Patient-reported treatment satisfaction and budget impact with rivaroxaban vs. standard therapy in elective cardioversion of atrial fibrillation: a post hoc analysis of the X-VeRT trial

Conclusion
The use of rivaroxaban in the setting of cardioversion resulted in greater patient satisfaction and cost savings, compared with that of VKA.

Source: Europace - February 25, 2016 Category: Cardiology Authors: Hohnloser, S. H., Cappato, R., Ezekowitz, M. D., Evers, T., Sahin, K., Kirchhof, P., Meng, I. L., van Eickels, M., Camm, A. J., on behalf of the X-VeRT Steering Committee and Investigators Tags: Atrial fibrillation Source Type: research